Presentation is loading. Please wait.

Presentation is loading. Please wait.

Networks of treatment comparisons for primary outcomes of SLE agents in patients with SLE. The size of the nodes (blue circles) corresponds to the number.

Published byChastity Jacobs Modified over 5 years ago

Similar presentations

Presentation on theme: "Networks of treatment comparisons for primary outcomes of SLE agents in patients with SLE. The size of the nodes (blue circles) corresponds to the number."— Presentation transcript:

1 Networks of treatment comparisons for primary outcomes of SLE agents in patients with SLE. The size of the nodes (blue circles) corresponds to the number of trials of the treatments. Networks of treatment comparisons for primary outcomes of SLE agents in patients with SLE. The size of the nodes (blue circles) corresponds to the number of trials of the treatments. Comparisons are linked with a line, the thickness of which corresponds to the number of trials that assessed the comparison. +, combined with; AZA, azathioprine; Beli, belimumab; CSA, cyclosporine; CYC-AZA, CYC followed by AZA; CYC, cyclophosphamide; GC, glucocorticoid; HD, high dose; LD, low dose; LEF, leflunomide; MD, moderate dose; MMF, mycophenolate mofetil; MTX, methotrexate; RTX, rituximab; SC, subcutaneous; TAC, tacrolimus. Jingru Tian et al. Lupus Sci Med 2018;5:e000253 ©2018 by Lupus Foundation of America

Download ppt "Networks of treatment comparisons for primary outcomes of SLE agents in patients with SLE. The size of the nodes (blue circles) corresponds to the number."

Similar presentations

Treatment of Vasculitis: immunesuppressives and biologics

Treatment of Vasculitis: immunesuppressives and biologics
Tuesday Clinical Case Conference Zae Kim. Therapy of ANCA-Associated Small Vessel Vasculitis.

Tuesday Clinical Case Conference Zae Kim. Therapy of ANCA-Associated Small Vessel Vasculitis.
Mechanism and New. Lupus Erythematosus - Medication NSAIDs may be used for musculoskeletal and mild systemic complaints, although ibuprofen.

Mechanism and New. Lupus Erythematosus - Medication NSAIDs may be used for musculoskeletal and mild systemic complaints, although ibuprofen.
Treatment of LN An European perspective Frédéric A. HOUSSIAU Department of Rheumatology Cliniques universitaires Saint-Luc LOUVAIN Medical School XXXV.

Treatment of LN An European perspective Frédéric A. HOUSSIAU Department of Rheumatology Cliniques universitaires Saint-Luc LOUVAIN Medical School XXXV.
Anti-rheumatic Drugs In Pregnancy And Breastfeeding

Anti-rheumatic Drugs In Pregnancy And Breastfeeding
Randomized Controlled Trials of Methotrexate & Mycophenolate in MG

Randomized Controlled Trials of Methotrexate & Mycophenolate in MG
Algorithm for diagnosis and initial therapy of systemic lupus erythematosus (SLE). For guidelines on management of lupus and lupus nephritis, see BH Hahn.

Algorithm for diagnosis and initial therapy of systemic lupus erythematosus (SLE). For guidelines on management of lupus and lupus nephritis, see BH Hahn.
Management of Myositis-Related Interstitial Lung Disease

Management of Myositis-Related Interstitial Lung Disease
Effects of MMF treatment in patients with SLE

Effects of MMF treatment in patients with SLE
Calcineurin Inhibitor-Related Cholestasis Complicating Lung Transplantation  Takahiro Oto, MD, Mikio Okazaki, MD, Ken Takata, MD, Moritoki Egi, MD, Masaomi.

Calcineurin Inhibitor-Related Cholestasis Complicating Lung Transplantation  Takahiro Oto, MD, Mikio Okazaki, MD, Ken Takata, MD, Moritoki Egi, MD, Masaomi.
EULAR Lupus Nephritis Trials Network Study Group 2017

EULAR Lupus Nephritis Trials Network Study Group 2017
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Anifrolumab inhibits type I interferon (IFN)-induced IFN-stimulated response element (ISRE) signalling. Anifrolumab inhibits type I interferon (IFN)-induced.

Anifrolumab inhibits type I interferon (IFN)-induced IFN-stimulated response element (ISRE) signalling. Anifrolumab inhibits type I interferon (IFN)-induced.
Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Nephrol. doi: /nrneph
Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.

Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.
Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.
Idiopathic Inflammatory Myopathies: Current Trends in Pathogenesis, Clinical Features, and Up-to-Date Treatment Recommendations  Floranne C. Ernste, MD,

Idiopathic Inflammatory Myopathies: Current Trends in Pathogenesis, Clinical Features, and Up-to-Date Treatment Recommendations  Floranne C. Ernste, MD,
Survival in chronic hypersensitivity pneumonitis (CHP) patients receiving immunosuppressive therapy. a) 5-year survival based on use of immunosuppressive.

Survival in chronic hypersensitivity pneumonitis (CHP) patients receiving immunosuppressive therapy. a) 5-year survival based on use of immunosuppressive.
Membranous nephropathy: When and how to treat

Membranous nephropathy: When and how to treat
Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.

Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.

Similar presentations

Ads by Google